Relmada Therapeutics annual depreciation and amortization
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
Relmada Therapeutics Depreciation & Amortization Growth & History (RLMD)
Relmada Therapeutics's depreciation and amortization was $0 for fiscal 2022.
View full Relmada Therapeutics company overviewRelmada Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | $0 | −$1,258 | — |
| 2021 | 2021-12-31 | $1,258 | −$2,494 | −66.47% |
| 2020 | 2020-12-31 | $3,752 | −$611 | −14.00% |
| 2019 · Dec 31 | 2019-12-31 | $4,363 | — | — |
| 2019 · Jun 30 | 2019-06-30 | $4,870 | $2,243 | +85.38% |
| 2018 | 2018-06-30 | $2,627 | −$82,644 | −96.92% |
| 2017 | 2017-06-30 | $85,271 | $30,452 | +55.55% |
| 2016 | 2016-06-30 | $54,819 | $45,563 | +492.25% |
| 2015 | 2015-06-30 | $9,256 | $6,926 | +297.25% |
| 2014 | 2014-06-30 | $2,330 | — | — |
| 2013 · Dec 31 | 2013-12-31 | $373 | — | — |
Relmada Therapeutics quarterly depreciation and amortization
Q1.14
Q1.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q3 2021 | 2021-09-30 | $0 | −$854 | — |
| Q2 2021 | 2021-06-30 | $452 | −$577 | −56.07% |
| Q1 2021 | 2021-03-31 | $806 | −$240 | −22.94% |
| Q3 2020 | 2020-09-30 | $854 | −$246 | −22.36% |
| Q2 2020 | 2020-06-30 | $1,029 | −$59 | −5.42% |
| Q1 2020 · Mar 31 | 2020-03-31 | $1,046 | −$29 | −2.70% |
| Q1 2020 · Sep 30 | 2019-09-30 | $1,100 | −$305 | −21.71% |
| Q4 2019 | 2019-06-30 | $1,088 | — | — |
| Q3 2019 | 2019-03-31 | $1,075 | $507 | +89.26% |
| Q2 2019 | 2018-12-31 | $1,302 | $720 | +123.71% |
| Q1 2019 | 2018-09-30 | $1,405 | $857 | +156.39% |
| Q3 2018 | 2018-03-31 | $568 | −$22,700 | −97.56% |
| Q2 2018 | 2017-12-31 | $582 | −$22,999 | −97.53% |
| Q1 2018 | 2017-09-30 | $548 | −$19,615 | −97.28% |
| Q3 2017 | 2017-03-31 | $23,268 | −$4,302 | −15.60% |
| Q2 2017 | 2016-12-31 | $23,581 | $20,626 | +698.00% |
| Q1 2017 | 2016-09-30 | $20,163 | $17,210 | +582.80% |
| Q3 2016 | 2016-03-31 | $27,570 | $25,122 | +1026.23% |
| Q2 2016 | 2015-12-31 | $2,955 | — | — |
| Q1 2016 | 2015-09-30 | $2,953 | −$641 | −17.84% |
| Q3 2015 | 2015-03-31 | $2,448 | $2,448 | — |
| Q1 2015 | 2014-09-30 | $3,594 | — | — |
| Q1 2014 · Mar 31 | 2014-03-31 | $0 | — | — |
Relmada Therapeutics depreciation and amortization trends
Between the periods ended 2013-12-31 and 2022-12-31, Relmada Therapeutics's depreciation and amortization decreased from $373 to $0, a change of −$373. The latest reported quarter, Q3 2021, shows $0.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relmada Therapeutics source filings ↗